Scholarly Index
Emi Dika
Azienda USL di Bologna; 3,871 total citations; 277 total publications; best world rank #40
Azienda USL di Bologna
3,871Total citations
277Total publications
33H-index
Published ranking records
| Field | Window | World rank | National rank | Impact score |
|---|---|---|---|---|
| Nonmelanoma Skin Cancer Studies | Lifetime | 361 | IT 25 | 96.52 |
| Nail Diseases and Treatments | Lifetime | 536 | IT 31 | 96.11 |
| Cutaneous lymphoproliferative disorders research | Lifetime | 450 | IT 41 | 95.92 |
| Cutaneous Melanoma Detection and Management | Lifetime | 643 | IT 52 | 95.86 |
| Cancer and Skin Lesions | Lifetime | 751 | IT 41 | 94.97 |
| Tattoo and Body Piercing Complications | Lifetime | 815 | IT 47 | 42.17 |
| Nonmelanoma Skin Cancer Studies | 2021-2025 | 40 | IT 9 | 97.25 |
| Cutaneous Melanoma Detection and Management | 2021-2025 | 80 | IT 11 | 97.21 |
| Cutaneous lymphoproliferative disorders research | 2021-2025 | 74 | IT 12 | 95.90 |
| Cancer and Skin Lesions | 2021-2025 | 108 | IT 12 | 90.37 |
| Melanoma and MAPK Pathways | 2021-2025 | 141 | IT 11 | 92.79 |
| Hedgehog Signaling Pathway Studies | 2021-2025 | 87 | IT 9 | 83.34 |
| Nail Diseases and Treatments | 2021-2025 | 443 | IT 25 | 81.34 |
| Genetic and rare skin diseases. | 2021-2025 | 116 | IT 12 | 76.00 |
| Infectious Diseases and Mycology | 2021-2025 | 291 | IT 27 | 77.80 |
| Tumors and Oncological Cases | 2021-2025 | 813 | IT 52 | 63.87 |